Table 1.
Current mRNA-based cancer vaccines in clinical trials.
| Cancer Type | NCT Number | Study Title | Study Status | Study Results | Interventions | Phases |
|---|---|---|---|---|---|---|
| Solid malignancies | NCT05198752 | A study of neoantigen mrna personalised cancer in patients with advanced solid tumors | recruiting | NO | Personalized neoantigen mRNA cancer vaccine | I |
| NCT05359354 | Safety and efficacy of personalized neoantigen vaccine in advanced solid tumors | recruiting | NO | Personalized neoantigen tumor vaccine | N/A | |
| NCT05579275 | Evaluate the safety and tolerability of jcxh-212 injection in the treatment of advanced malignant solid tumors | recruiting | NO | Neoantigen mRNA cancer vaccine | I | |
| NCT05714748 | Application of mRNA immunotherapy technology in epstein-barr virus-related refractory malignant tumors | recruiting | NO | EBV mRNA vaccine | I | |
| NCT05916248 | Personalized tumor vaccines and pembrolizumab in patients with advanced solid tumors | recruiting | NO | Personalized neoantigen tumor vaccine | I | |
| NCT05940181 | A safety and efficacy study of xh001 combined with sintilimab injection in advanced solid tumors | recruiting | NO | Neoantigen mRNA cancer vaccine with sintilimab | N/A | |
| NCT05942378 | A study of hrxg-k-1939 and adebrelimab in patients with advanced solid tumors | not yet recruiting | NO | Personalized neoantigen tumor vaccine and Adebrelimab | I | |
| NCT05949775 | Clinical study of mRNA vaccine in patients with advanced malignant solid tumors | not yet recruiting | NO | Neoantigen mRNA personalized cancer vaccine | N/A | |
| Gastrointestinal malignancies | NCT03468244 | Clinical study of personalized mRNA vaccine encoding neoantigen in patients with advanced digestive system neoplasms | unknown | NO | Personalized mRNA tumor vaccine | N/A |
| NCT04161755 | Study of personalized tumor vaccines and a pd-l1 blocker in patients with pancreatic cancer that can be treated with surgery | active, not recruiting | YES | Atezolizumab, personalized tumor vaccines, mFOLFIRINOX | I | |
| NCT05192460 | Safety and efficacy of personalized neoantigen vaccine in advanced gastric cancer, esophageal cancer and liver cancer | recruiting | NO | Neoantigen tumor vaccine with or without PD-1/L1 | N/A | |
| NCT05456165 | Study of an individualized vaccine targeting neoantigens in combination with immune checkpoint blockade for patients with colon cancer | terminated | NO | Individualized neoantigen tumor vaccine with or without PD-1/L1 | II | |
| NCT05738447 | Application of mRNA immunotherapy technology in hepatitis b virus-related refractory hepatocellular carcinoma | recruiting | NO | HBV mRNA vaccine | I | |
| NCT05761717 | Clinical study of mRNA vaccine in patients with liver cancer after operation | not yet recruiting | NO | Neoantigen mRNA personalized cancer vaccine in combination with Stintilimab | N/A | |
| NCT05916261 | Personalized tumor vaccines and pabolizumab in patients with advanced pancreatic cancer | recruiting | NO | Personalized neoantigen tumor vaccine | I | |
| NCT05981066 | A clinical study of mRNA vaccine (abor2014/ipm511) in patients with advanced hepatocellular carcinoma | recruiting | NO | Neoantigen vaccine, I.M injection | N/A | |
| NCT06019702 | Clinical study of personalized mRNA vaccine encoding neoantigen alone in subjects with advanced digestive system neoplasms | recruiting | NO | iNeo-Vac-R01 | I | |
| Prostate cancer | NCT02140138 | An open label randomised trial of rnactive cancer vaccine in high risk and intermediate risk patients with prostate cancer | terminated | NO | mRNA vaccines (targeting 6 prostate-specific antigens) with needle-free injection device | II |
| NCT04382898 | Pro-merit (prostate cancer messenger RNA immunotherapy) | recruiting | NO | mRNA vaccines (targeting 5 antigens) with Cemiplimab | I/II | |
| NSCLC | NCT03164772 | Phase 1/2 study of combination immunotherapy and messenger ribonucleic acid (mRNA) vaccine in subjects with NSCLC | completed | YES | An mRNA vaccine with or without Durvalumab and Tremelimumab | I/II |
| Melanoma | NCT05264974 | Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-pd-1 antibody therapy | not yet recruiting | NO | Autologous tumor mRNA loaded DOTAP liposome vaccine | I |
| Glioblastoma | NCT05938387 | Safety and tolerability of cvgbm in adults with newly diagnosed mgmt-unmethylated glioblastoma or astrocytoma | recruiting | NO | Different doses of an mRNA vaccine | I |
| Pulmonary Osteosarcoma | NCT05660408 | Study of RNA-lipid particle (RNA-LP) vaccines for recurrent pulmonary osteosarcoma (OSA) | not yet recruiting | NO | RNA-LP vaccine | I/II |
| Melanoma, Gastrointestinal, Genitorinary | NCT03480152 | Messenger mRNA)-based, personalized cancer vaccine against neoantigens expressed by the autologous cancer | terminated | YES | National Cancer Institute (NCI)-4650, an mRNA-based, personalized cancer vaccine | I/II |
| Esophageal cancer and NSCLC | NCT03908671 | Clinical study of personalized mRNA vaccine encoding neoantigen in patients with advanced esophageal cancer and non-small cell lung cancer | recruiting | NO | Personalized mRNA tumor vaccine | N/A |
| NSCLC, pancreatic cancer, and colorectal cancer | NCT03948763 | A study of mRNA-5671/v941 as monotherapy and in combination with pembrolizumab (v941-001) | completed | NO | mRNA 5671 with pembrolizumab | I |
Note: N/A, Not Applicable.